3D-printed organ developer BioLife4D seeks $50 million IPO

Biological 3D printing developer BioLife4D has filed for a $50 million initial public offering as it looks to commercialize its cardiac tissue regeneration and organ replacement processes. The Chicago-based company said yesterday it is developing technologies with an end goal of creating a 3D bioprinted viable human heart suitable for transplant. Funds from the offering